As of the information available from the provided sources, there are no specific updates on the generic launch of Onglyza (saxagliptin). Onglyza is a prescription medication used to treat type 2 diabetes. It works by increasing the release of insulin and reducing the amount of glucose produced by the liver.

According to DrugPatentWatch, which provides information on drug patents, the patent for Onglyza is set to expire in February 2022 [1]. However, it is important to note that the expiration of a patent does not automatically guarantee the immediate availability of a generic version. Generic manufacturers must still obtain approval from regulatory authorities and may face legal challenges from the brand-name manufacturer.

In a news release from Kyowa Kirin, the company announced a settlement agreement with Actavis regarding patent litigation related to Onglyza [2]. The details of the settlement were not provided in the source, so it is unclear if it directly pertains to the generic launch of Onglyza.

Additionally, the source from GaBI Online reports on Actavis settling patent litigation related to Nuvigil and challenging the patent for Onglyza [3]. Again, it is not explicitly mentioned if this settlement directly impacts the generic launch of Onglyza.

In conclusion, based on the provided sources, there are no specific updates on the generic launch of Onglyza. It is important to consult with healthcare professionals or reliable sources for the most up-to-date and accurate information regarding the availability of generic versions of Onglyza.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ONGLYZA
[2] Kyowa Kirin: https://www.kyowakirin.com/media_center/news_releases/2013/e20130708_01.html
[3] GaBI Online: https://www.gabionline.net/generics/news/Actavis-settles-Nuvigil-patent-litigation-challenges-Onglyza-patent